Upon intravenous transfer of a single dose of either 5 × 106 NKp30-CD28 TCRKO or likewise 5 × 106 NKp30-CD137 CAR TCRKO T cells and anti-CD19-CD28 CAR TCRKO T cells as specificity control supplemented with 1.000 IU IL-2/dose, tumor growth and overall survival of A375 tumor engrafted NSG recipients was determined (Figure 6B,C). Here, TNFRSF9 is linked to neoplasm.